Additionally, CPT-treated obese mice showed reduced hepatic lipid content and liver weight (Fig 2F and 2G, S7C and S7D Fig), accompanied with reductions in levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Fig 2H, S7E Fig), suggesting an improvement in obesity-associated fatty liver and liver damage upon CPT treatment. The gene discussed is GPT; the disease is fatty liver disease.